文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

串联自体干细胞移植与单次移植对高危神经母细胞瘤患者无事件生存的影响:一项随机临床试验

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

该随机临床试验纳入355例30岁及以下高危神经母细胞瘤患者,比较串联自体移植(176例)与单次移植(179例)的无事件生存(EFS)。串联移植组3年EFS为61.6%(95%CI 54.3%-68.9%),单次移植组为48.4%(95%CI 41.0%-55.7%),单侧对数秩检验P=.006。作者结论为串联移植显著改善EFS,但因随机化率低,结果可能不能代表全部高危神经母细胞瘤患者。

要点

  • 串联移植组3年EFS 61.6% vs 单次移植组48.4%,单侧对数秩检验P=.006。
  • 串联移植与单次移植最常见显著毒性为黏膜毒性(11.7% vs 15.4%)和感染性毒性(17.9% vs 18.3%)。
  • 作者指出因随机化率低,结果可能不能代表全部高危神经母细胞瘤患者。

核心结论

  • 在30岁及以下高危神经母细胞瘤患者中,串联移植较单次移植带来显著更优的无事件生存。
  • 但因随机化率低,该结果可能不能代表全部高危神经母细胞瘤患者。

研究设计与样本

  • 随机临床试验,2007年11月至2012年2月在美国、加拿大、瑞士、澳大利亚和新西兰的142个儿童肿瘤协作组中心入组患者。
  • 共652例符合条件的高危神经母细胞瘤患者入组,其中355例随机化;串联移植组176例,单次移植组179例。
  • 随机化患者中位诊断年龄36.1个月,女性152例(42.8%)。
  • 研究设计为检验串联移植优于单次移植的单侧假设。

主要发现

  • 随机化后3年无事件生存:串联移植组61.6%(95%CI 54.3%-68.9%),单次移植组48.4%(95%CI 41.0%-55.7%),单侧对数秩检验P=.006。
  • 652例符合条件患者中,297例未随机化:非随机分配27例、不符合随机化条件62例、未接受治疗1例、医生或家长偏好207例。
  • 355例随机化患者中,297例(83.7%)完成研究,21例(5.9%)在完成方案治疗后失访。
  • 随机化后无事件且随访的181例患者,中位随访时间5.6年(范围0.6-8.9年)。
  • 串联移植与单次移植后最常见显著毒性:黏膜毒性11.7% vs 15.4%,感染性毒性17.9% vs 18.3%。

关键数值与推荐

  • 主要结局为从随机化至首次事件(复发、进展、第二恶性肿瘤或任何原因死亡)的无事件生存。
  • 串联移植方案为噻替哌/环磷酰胺后接减剂量卡铂/依托泊苷/美法仑;单次移植方案为卡铂/依托泊苷/美法仑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因随机化率低,研究结果可能不能代表全部高危神经母细胞瘤患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Induction chemotherapy followed by high-dose therapy with autologous stem cell transplant and subsequent antidisialoganglioside antibody immunotherapy is standard of care for patients with high-risk neuroblastoma, but survival rate among these patients remains low. OBJECTIVE: To determine if tandem autologous transplant improves event-free survival (EFS) compared with single transplant. DESIGN, SETTING, AND PARTICIPANTS: Patients were enrolled in this randomized clinical trial from November 2007 to February 2012 at 142 Children's Oncology Group centers in the United States, Canada, Switzerland, Australia, and New Zealand. A total of 652 eligible patients aged 30 years or younger with protocol-defined high-risk neuroblastoma were enrolled and 355 were randomized. The final date of follow-up was June 29, 2017, and the data analyses cut-off date was June 30, 2017. INTERVENTIONS: Patients were randomized to receive tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176) or single transplant with carboplatin/etoposide/melphalan (n = 179). MAIN OUTCOMES AND MEASURES: The primary outcome was EFS from randomization to the occurrence of the first event (relapse, progression, secondary malignancy, or death from any cause). The study was designed to test the 1-sided hypothesis of superiority of tandem transplant compared with single transplant. RESULTS: Among the 652 eligible patients enrolled, 297 did not undergo randomization because they were nonrandomly assigned (n = 27), ineligible for randomization (n = 62), had no therapy (n = 1), or because of physician/parent preference (n = 207). Among 355 patients randomized (median diagnosis age, 36.1 months; 152 [42.8%] female), 297 patients (83.7%) completed the study and 21 (5.9%) were lost to follow-up after completing protocol therapy. Three-year EFS from the time of randomization was 61.6% (95% CI, 54.3%-68.9%) in the tandem transplant group and 48.4% (95% CI, 41.0%-55.7%) in the single transplant group (1-sided log-rank P=.006). The median (range) duration of follow-up after randomization for 181 patients without an event was 5.6 (0.6-8.9) years. The most common significant toxicities following tandem vs single transplant were mucosal (11.7% vs 15.4%) and infectious (17.9% vs 18.3%). CONCLUSIONS AND RELEVANCE: Among patients aged 30 years or younger with high-risk neuroblastoma, tandem transplant resulted in a significantly better EFS than single transplant. However, because of the low randomization rate, the findings may not be representative of all patients with high-risk neuroblastoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00567567.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019. PMID: 31454045. doi:10.1001/jama.2019.11642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。